Genesco Q4 Profit Down, Comps Up; Issues FY24 Forecast; Stock Down In Pre Market

Specialty retailer Genesco Inc. (GCO) reported Thursday that its fourth-quarter net earnings declined to $38.95 million from last year's $62.14 million. Earnings per share were $3.21, down from $4.41 a year ago.

Earnings from continuing operations were $39.20 million or $3.23 per share, compared to $62.2 million or $4.41 per share in the fourth quarter last year.

Adjusted earnings from continuing operations were $37.1 million or $3.06 per share, compared to $49.1 million, or $3.48 per share last year

Net sales were $725.02 million, slightly lower than last year's $727.66 million. Sales increased 7 percent over fiscal 2020, prior to the pandemic.

Excluding the impact of lower exchange rates, net sales increased 2 percent from last year.

Comparable sales went up 5 percent, with Same Store Sales growth of 1 percent and direct sales growth of 21 percent.

Looking ahead for fiscal 2024, the company forecasts adjusted earnings per share to range between $5.10 and $5.90, with an expectation that earnings per share for the year will be near the mid-point of the range.

The company noted that a greater percentage of this year's earnings will be coming in the second half.

Sales for the year are expected to be flat to up 2 percent, or down 1 percent to up 1 percent, excluding the 53rd week this year.

In fiscal 2023, earnings per share from continuing operations were $5.69, and adjusted earnings per share from continuing operations were $5.59.

In pre-market activity on the NYSE, Genesco shares were losing around 5.8 percent to trade at $44.99.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT